Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Doctors explain why headaches are popular among Wegovy and Ozempic patients and how to treat and prevent them, including ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Zepbound is an FDA-approved injectable weight loss medication. Find out more about Zepbound for weight loss, including how it works and what experts say.

Skye’s Nimacimab shows promise in obesity treatment with lean mass preservation. Phase 2a results slated for 2025 could drive ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...

Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...

Zepbound shows fewer side effects than Wegovy in obesity treatment study Research highlights Zepbounds advantages over Wegovy in treating obesity with less nausea.

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...